HSP90 as a novel molecular target in non-small-cell lung cancer
Authors:
Open Access
- 1 March 2016
- journal article
- review article
- Published by Taylor & Francis in Lung Cancer: Targets and Therapy
- Vol. ume 7, 11-17
Abstract
Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.Keywords
This publication has 35 references indexed in Scilit:
- The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancerCancer Science, 2012
- Radiosensitization of Normoxic and Hypoxic H1339 Lung Tumor Cells by Heat Shock Protein 90 Inhibition Is Independent of Hypoxia Inducible Factor-1αPLOS ONE, 2012
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvestigational New Drugs, 2012
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC modelsOncogene, 2011
- Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitorsCell Cycle, 2009
- Targeting HSP90 for cancer therapyBritish Journal of Cancer, 2009
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to PaclitaxelCancer Research, 2008
- Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibitionBritish Journal of Cancer, 2007
- Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitorsEndocrine-Related Cancer, 2006
- Heat shock protein 90Current Opinion in Oncology, 2003